ABBISKO-B (02256) affiliate Glory Pharmaceuticals has completed the first dose of patient in the Phase 1 clinical trial of the innovative PRMT5*MTA inhibitor ABSK131.
Hoyu Group B (02256) announces that its subsidiary, Shanghai Hoyu Biomedical Technology Co., Ltd. (Hoyu Medical...
ABBISKO-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that its research-based innovative PRMT5*MTA inhibitor ABSK131 has completed the first patient dosing in a phase 1 clinical trial in patients with MTAP-deficient advanced/metastatic solid tumors. In March 2025, ABSK131 received IND approval from the China National Medical Products Administration Drug Evaluation Center. In December 2024, ABSK131 received IND approval from the US Food and Drug Administration.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
